文献速递神经肿瘤

ACTION:ONC201(多达维普隆)治疗新诊断H3 K27M突变型弥漫性胶质瘤的随机3期研究

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
PubMed 文献 · Neuro Oncol · 2024-01-01

ACTION是一项随机、双盲、安慰剂对照、平行组、国际3期研究,评估ONC201(多达维普隆)在新诊断H3 K27M突变型弥漫性胶质瘤患者中的疗效。患者完成标准一线放疗后按1:1:1随机接受安慰剂、每周一次多达维普隆或连续两天每周两次多达维普隆。主要疗效终点为总生存期(OS)和无进展生存期(PFS),PFS由盲法独立中心评审按RANO-HGG标准评估。

要点

  • ACTION研究针对新诊断H3 K27M突变型弥漫性胶质瘤患者,完成一线放疗后随机分组。
  • 主要终点为OS和PFS,PFS采用RANO-HGG标准盲法独立中心评审。
  • 入组要求组织学确诊H3 K27M突变、Karnofsky/Lansky体能状态评分≥70、完成一线放疗,随机时体重≥10 kg。

核心结论

  • ONC201(多达维普隆)此前在复发性疾病患者中显示疗效,本3期试验评估其在新诊断H3 K27M突变型胶质瘤患者中的作用。

研究设计与样本

  • ACTION(NCT05580562)是一项随机、双盲、安慰剂对照、平行组、国际3期研究。
  • 患者完成标准一线放疗后按1:1:1随机接受安慰剂、每周一次多达维普隆或连续两天每周两次多达维普隆。
  • 主要疗效终点为总生存期(OS)和无进展生存期(PFS),PFS由盲法独立中心评审按RANO-HGG标准评估。
  • 次要目标包括安全性、其他疗效终点、临床获益和生活质量。
  • 入组标准:组织学确诊H3 K27M突变型弥漫性胶质瘤、Karnofsky/Lansky体能状态评分≥70、完成一线放疗;年龄不限,但随机时体重须≥10 kg。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: H3 K27M-mutant diffuse glioma primarily affects children and young adults, is associated with a poor prognosis, and no effective systemic therapy is currently available. ONC201 (dordaviprone) has previously demonstrated efficacy in patients with recurrent disease. This phase 3 trial evaluates ONC201 in patients with newly diagnosed H3 K27M-mutant glioma. METHODS: ACTION (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group, international phase 3 study of ONC201 in newly diagnosed H3 K27M-mutant diffuse glioma. Patients who have completed standard frontline radiotherapy are randomized 1:1:1 to receive placebo, once-weekly dordaviprone, or twice-weekly dordaviprone on 2 consecutive days. Primary efficacy endpoints are overall survival (OS) and progression-free survival (PFS); PFS is assessed by response assessment in neuro-oncology high-grade glioma criteria (RANO-HGG) by blind independent central review. Secondary objectives include safety, additional efficacy endpoints, clinical benefit, and quality of life. Eligible patients have histologically confirmed H3 K27M-mutant diffuse glioma, a Karnofsky/Lansky performance status ≥70, and completed first-line radiotherapy. Eligibility is not restricted by age; however, patients must be ≥10 kg at time of randomization. Patients with a primary spinal tumor, diffuse intrinsic pontine glioma, leptomeningeal disease, or cerebrospinal fluid dissemination are not eligible. ACTION is currently enrolling in multiple international sites.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Arrillaga-Romany I, Lassman A, McGovern SL, et al. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro Oncol. 2024. PMID: 38445964. doi:10.1093/neuonc/noae031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。